Nvidia's 2025 star stock crumbles in an unexpected turn

CoreWeave's Q2 2025 earnings reported revenue surging 206% year-over-year to $1.21 billion, exceeding forecasts, and a narrower adjusted loss per share. However, a wider-than-expected net loss of $290.5 million and a negative gross margin of -11% led to a 10% after-hours stock plunge. This reaction highlights investor sensitivity to profitability metrics despite strong top-line growth and a substantial $30.1 billion revenue backlog, as the AI cloud data center firm aggressively expands and navigates power constraints and analyst concerns regarding debt and potential margin compression from intensifying competition for GPU access.

Analysis

CoreWeave's Q2 2025 earnings report presents a stark contrast between exceptional top-line growth and deteriorating profitability, triggering a significant after-hours stock decline. The company's revenue surged 206% year-over-year to $1.21 billion, comfortably beating analysts' $1.08 billion forecast, and its adjusted loss of $0.21 per share was marginally better than the expected $0.22 loss. This performance, fueled by what the CEO calls "unprecedented demand for AI infrastructure," is further supported by a substantial $30.1 billion revenue backlog. However, the market's negative reaction, a 10% share price drop, was driven by the bottom-line figures: the net loss widened to $290.5 million, far exceeding the anticipated $199 million, and the gross margin collapsed to a negative 11% from negative 1% a year prior. This indicates that the costs associated with aggressive expansion, including a $1.4 billion acquisition and a pending $9 billion purchase of Core Scientific, are currently outpacing revenue gains. Analyst commentary from JPMorgan, while raising its price target to $135, also noted key risks such as high debt levels and potential margin compression as competitors neutralize CoreWeave's key advantage of preferential access to Nvidia GPUs, a concern now amplified by the negative margin results.

Key Decisions for Investors

• Investors should weigh the immense top-line momentum, evidenced by 206% revenue growth and a $30.1 billion backlog, against significant profitability concerns reflected in the -11% gross margin and widening net loss.
• The aggressive M&A strategy, including the pending $9 billion Core Scientific deal, introduces substantial integration risk and will likely increase debt, warranting close scrutiny of the company's balance sheet in upcoming quarters.
• Given the stock has already appreciated over 270% since its IPO, the market's sharp negative reaction to margin pressure suggests a re-evaluation of the company's valuation, particularly as its competitive advantage in GPU access may diminish over time.